GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Capex-to-Operating-Income

Diamyd Medical AB (OSTO:DMYD B) Capex-to-Operating-Income : 0.00 (As of Feb. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Diamyd Medical AB's Capital Expenditure for the three months ended in Feb. 2025 was kr-0.46 Mil. Its Operating Income for the three months ended in Feb. 2025 was kr-45.69 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Diamyd Medical AB Capex-to-Operating-Income Historical Data

The historical data trend for Diamyd Medical AB's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Capex-to-Operating-Income Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 - - - -

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diamyd Medical AB's Capex-to-Operating-Income

For the Biotechnology subindustry, Diamyd Medical AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Capex-to-Operating-Income falls into.


;
;

Diamyd Medical AB Capex-to-Operating-Income Calculation

Diamyd Medical AB's Capex-to-Operating-Income for the fiscal year that ended in Aug. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-8.025) / -147.274
=N/A

Diamyd Medical AB's Capex-to-Operating-Income for the quarter that ended in Feb. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.458) / -45.687
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB  (OSTO:DMYD B) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Diamyd Medical AB Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines